# Nuclear Medicine Cheatsheet

## Table of Contents
- [Basic Principles](#basic-principles)
- [Types of Radiation](#types-of-radiation)
- [Imaging Techniques](#imaging-techniques)
- [Radiopharmaceuticals](#radiopharmaceuticals)
- [Clinical Applications](#clinical-applications)
- [Therapeutic Applications](#therapeutic-applications)
- [Dosimetry & Safety](#dosimetry--safety)
- [Instrumentation & Quality Control](#instrumentation--quality-control)
- [Recent Advances & Future Trends](#recent-advances--future-trends)

## Basic Principles
### Definition:
#### ğŸ“Œ **Nuclear Medicine:** 
- A branch of medicine and medical imaging that uses radioactive substances (radiopharmaceuticals) for diagnosis, treatment, and research.

### ğŸ“Œ **Radiopharmaceuticals:**
- **What are they?** 
  - **Radiopharmaceutical** = ğŸ’Š (Pharmaceutical) + â˜¢ï¸ (Radioactive Isotope)
- **Purpose:** 
  - Radiopharmaceuticals are taken up by specific organs, tissues, or cells, allowing them to be visualized during imaging or to deliver therapeutic radiation to targeted sites.

[Back to top](#nuclear-medicine-cheatsheet)

## Types of Radiation


### ğŸ”µ Alpha Radiation (Î±):

**General Characteristics:**

- ğŸ“Œ Composed of 2 protons and 2 neutrons.
- ğŸ§² Positively charged.
- ğŸš§ Short range in tissues and can be stopped by a sheet of paper or human skin.

**Common Alpha Emitters in Nuclear Medicine:**

- **Radium-223 (Ra-223)**
  - ğŸ“ **Usage:** Treatment of bone metastases in patients with castration-resistant prostate cancer.
  - âš› **Decay Mechanism:** Undergoes a series of alpha decays to become stable lead.
  - ğŸ¯ **Why Used:** The emitted alpha particles are high linear energy transfer (LET) particles, meaning they can cause a significant amount of local damage, making them useful for targeted therapy of metastatic lesions in bones.

### ğŸ”´ Beta Radiation (Î²):

**General Characteristics:**

- â– Beta Minus (Î²-) involves emission of electrons.
- â• Beta Plus (Î²+) involves emission of positrons.
- ğŸš€ Longer range than alpha particles but less than gamma rays.

**Common Beta Emitters in Nuclear Medicine:**

- **Yttrium-90 (Y-90)**
  - ğŸ“ **Usage:** Used in radioimmunotherapy and for liver cancer treatments using microspheres.
  - âš› **Decay Mechanism:** Î²- emitter that decays to stable Zirconium-90.
  - ğŸ¯ **Why Used:** Due to its relatively long half-life and pure beta emission, it delivers a high dose of radiation to targeted tissues.
  
- **Fluorine-18 (F-18)**
  - ğŸ“ **Usage:** Most commonly used in FDG-PET imaging for oncology.
  - âš› **Decay Mechanism:** Î²+ emitter that decays into Oxygen-18.
  - ğŸ¯ **Why Used:** Provides valuable metabolic information about tissues, with tumors typically showing increased FDG uptake due to higher metabolic activity.

### ğŸŒŒ Gamma Radiation (Î³):

**General Characteristics:**

- ğŸ’¡ Electromagnetic radiation (high-energy photons).
- ğŸ›¡ï¸ Deeply penetrating and requires shielding.

**Common Gamma Emitters in Nuclear Medicine:**

- **Technetium-99m (Tc-99m)**
  - ğŸ“ **Usage:** The most widely used radionuclide in diagnostic nuclear medicine. Used in a variety of scans such as bone scans, myocardial perfusion imaging, and renal scans.
  - âš› **Decay Mechanism:** Emits gamma radiation and decays to stable Technetium-99.
  - ğŸ¯ **Why Used:** Its 6-hour half-life is long enough to conduct the necessary diagnostic tests but short enough to minimize radiation dose to the patient. The emitted gamma energy (140 keV) is ideal for imaging with a gamma camera.
  
- **Iodine-131 (I-131)**
  - ğŸ“ **Usage:** Used for both diagnostic imaging and therapy, particularly for thyroid diseases.
  - âš› **Decay Mechanism:** Beta and gamma emitter.
  - ğŸ¯ **Why Used:** Accumulates in the thyroid gland, allowing imaging or targeted destruction of thyroid tissue.


[Back to top](#nuclear-medicine-cheatsheet)

## Imaging Techniques 


### 1. **Gamma Camera** ğŸ“¸

- **Principle**: A gamma camera captures gamma radiation from radiopharmaceuticals inside a patient's body, thereby providing a two-dimensional image.

- **Components**:
    - ğŸŒ€ **Collimator**: A lead shield with holes that only allows gamma rays traveling in specific directions to pass through, ensuring spatial resolution.
    - ğŸ› **Detector Crystal**: Typically made of sodium iodide or cesium iodide, this crystal emits flashes of light (scintillations) when hit by gamma rays.
    - ğŸ–¥ **Photomultiplier Tubes (PMTs)**: Positioned behind the crystal, these tubes detect the light from the crystal and convert it into an electrical signal.
    - ğŸ” **Computer System**: Takes the signals from the PMTs and constructs an image.

- **Operation**: After a patient is administered a radiopharmaceutical, the gamma camera captures emitted gamma rays, and a computer processes this data into an image.

- **Indications**:
    - Bone Scans: Detect bone metastases, fractures, infections, or inflammatory disorders.
    - Thyroid Scans: Evaluate thyroid function or detect tumors.
    - Renal Scans: Assess kidney function and drainage.
    - Cardiac Stress Tests: Determine areas of low blood flow.

- **Common Tracers**:
    - Technetium-99m (Tc-99m): Versatile and can be combined with various molecules to target specific organs.
    - Iodine-123 (I-123): Common for thyroid scans.

### 2. **SPECT (Single Photon Emission Computed Tomography)** ğŸ”„

- **How it Functions**: A SPECT scanner acquires multiple 2D images from various angles. A computer then uses these images to produce a 3D image, providing more detail about the body's internal structures.

- **Clinical Applications**: 
    - Brain: Analyze blood flow and detect abnormalities.
    - Heart: Detect coronary artery disease or myocardial infarctions.
    - Bones: Spot fractures, infections, or tumors.

- **Advantages over Planar Imaging**:
    - Provides 3D visualization, allowing for more accurate localization of lesions.
    - Offers better contrast resolution.

- **Common Tracers**:
    - Technetium-99m (Tc-99m): Modified for various target organs, including the brain, heart, and bones.

### 3. **PET (Positron Emission Tomography)** ğŸŒŒ

- **Basics of Positron Emission**: After a patient is injected with a positron-emitting radionuclide, the positron encounters an electron in the body. Their mutual annihilation produces two gamma rays, which travel in opposite directions and are captured by the PET camera.

- **Commonly Used Radionuclides**:
    - Fluorine-18 FDG (F-18 FDG): Sugar molecule analog that, when taken up by cells, indicates metabolic activity.

- **Clinical Applications**:
    - Oncology: Determine the stage of cancers, assess treatment efficacy, and detect recurrences.
    - Neurology: Diagnose conditions like Alzheimer's and evaluate epilepsy.
    - Cardiology: Evaluate perfusion and metabolism of the heart muscle.

- **Common Tracers**:
    - Fluorine-18 FDG: Used in tumor imaging, highlighting areas of increased glucose metabolism.
    - Rubidium-82: Cardiac PET imaging to assess myocardial blood flow.

### 4. **Hybrid Imaging** ğŸŒğŸ”—

- **Principle**: Merges anatomical (from CT or MRI) and functional (from SPECT or PET) images, allowing for enhanced diagnostic capability.

- **Techniques**:
    - **PET/CT**: Combines metabolic PET images with CT's anatomical detail, often used for cancer imaging.
    - **SPECT/CT**: Merges functional SPECT with anatomical CT, common in cardiac and orthopedic imaging.

- **Advantages**:
    - Pinpoint accuracy in lesion localization.
    - Better differentiation between benign and malignant lesions.
    - Streamlines patient management by reducing the need for multiple scans.

- **Common Tracers**:
    - Vary based on the specific modality and indication. For instance, a PET/CT for cancer diagnosis might use Fluorine-18 FDG, while a SPECT/CT for cardiac imaging could utilize Technetium-99m.


[Back to top](#nuclear-medicine-cheatsheet)

## Radiopharmaceuticals


### ğŸ› **Production of Radiopharmaceuticals**


#### ğŸŒ€ **Cyclotrons in Radiopharmacy**

**What are Cyclotrons? ğŸ¤”**
In radiopharmacy, cyclotrons are particle accelerators designed to produce high-energy protons or deuterons. These particles then bombard target materials to produce specific radionuclides.

**How Do Cyclotrons Work? ğŸ”**
Electric fields are set up in a cyclical pattern, causing the charged particles to spiral outwards, gaining energy as they go. The high-energy particles then strike a target material, causing nuclear reactions and the production of radionuclides.

**Applications in Radiopharmacy ğŸŒŸ:**
- Production of Fluorine-18 for PET imaging.
- Creation of other radionuclides for various diagnostic and therapeutic applications.

---

#### ğŸŒ‹ **Nuclear Reactors in Radiopharmacy**

**What are Nuclear Reactors? ğŸ¤”**
In the context of radiopharmacy, nuclear reactors are facilities that initiate, control, and sustain nuclear fission reactions, producing a slew of radionuclides in the process.

**How Do Nuclear Reactors Work? âš›ï¸**
A reactor uses controlled fission reactions of enriched Uranium-235 or other fissile materials. As these atoms split, they release energy and a variety of radionuclides.

**Key Role in Radiopharmacy ğŸ’¡:**
- Main source for producing Molybdenum-99.
- Enables production of several other radionuclides for medical use.

---

#### ğŸ› **Generators in Radiopharmacy**

**What are Generators? ğŸ¤”**
In radiopharmacy, a generator is a system that allows for the production of a short-lived daughter radionuclide from a longer-lived parent radionuclide. The daughter radionuclide is then used in medical applications, especially when it has a short half-life and cannot be easily transported from a central production facility to hospitals or imaging centers.

**How Do Generators Work? ğŸ”„**
The generator contains a parent radionuclide that decays into a daughter radionuclide. Once the daughter is formed, it can be extracted or "eluted" from the generator using an appropriate solvent (usually saline solution). This process is often referred to as "milking" the generator.

**The Mo-99/Tc-99m Generator: A Prime Example ğŸŒŸ**
The Molybdenum-99/Technetium-99m (Mo-99/Tc-99m) generator is the most well-known and widely used generator system in nuclear medicine.

- **Parent Radionuclide (Mo-99) â³:**
  - Half-life: 66 hours.
  - Decay Product: Technetium-99m (Tc-99m) through beta decay.
- **Daughter Radionuclide (Tc-99m) ğŸ“¸:**
  - Half-life: 6 hours.
  - Usage: Diagnostic imaging in nuclear medicine.

---

### ğŸŒ **Common and Exotic Radiopharmaceuticals in Medical Imaging**

#### **Technetium-99m Based Agents ğŸ§ª**

**Understanding Tc-99m: ğŸ¤”**
Tc-99m is a metastable gamma-emitting nuclear isomer. Due to its favorable radiation properties and short half-life, it's ideal for various imaging procedures.

**Applications ğŸŒŸ:**
- Bone scans using Tc-99m MDP.
- Myocardial perfusion imaging.
- Renal function assessments with Tc-99m MAG3.

#### **Fluorodeoxyglucose (F-18 FDG) ğŸ¬**

**Unpacking F-18 FDG: ğŸ¤”**
It's a glucose analog where a radioactive fluorine atom replaces hydroxyl. Tumors, being highly metabolic, consume more glucose, making F-18 FDG invaluable in oncology imaging.

**Applications ğŸŒŸ:**
- PET imaging to visualize metabolic activity in tumors.

---

### ğŸ”„ **Pharmacokinetics of Radiopharmaceuticals**

#### **Absorption in the Body ğŸ’‰**

**What is Absorption? ğŸ¤”**
It's the process by which radiopharmaceuticals move from the administration site into the bloodstream.

**Methods ğŸŒŸ:**
- Most common: Intravenous injection.
- Others: Inhalation or oral intake.

#### **Distribution in Tissues ğŸŒ**

**Understanding Distribution: ğŸ¤”**
After entering the bloodstream, the radiopharmaceutical is carried to various body tissues. The patterns depend on the specific agent and its chemical properties.

**Factors Influencing Distribution ğŸŒŸ:**
- Blood flow to organs.
- Binding to plasma proteins.
- Compound's lipophilicity.



[Back to top](#nuclear-medicine-cheatsheet)

## Clinical Applications

### **1ï¸âƒ£ Diagnostic and Staging Modalities in Oncology**
Nuclear medicine plays a pivotal role in the diagnosis, staging, and monitoring of various cancers. Through the use of different radiopharmaceuticals, the metabolic activity of tumors and their response to treatments can be studied in depth.

**A. FDG-PET/CT ğŸ“¸**

- **What is it?** PET using F-18 Fluorodeoxyglucose (FDG) combined with CT provides both metabolic and anatomical information. 
- **How it works?** Cancer cells often have increased glucose metabolism. FDG, a glucose analog, accumulates in these hypermetabolic cells, which can be detected with PET. 
- **Applications**:
  - **Initial Staging**: Helps determine the extent of disease at diagnosis.
  - **Re-staging**: Assesses the body post-treatment to check for residual or recurrent disease.
  - **Therapeutic Monitoring**: Evaluates how well a tumor is responding to therapy.
  - **Prognostication**: High uptake (SUV) can be correlated with a more aggressive tumor phenotype.

**B. Gallium-68 DOTA Peptides (Somatostatin Receptor Imaging) ğŸ“¸**

- **What is it?** Gallium-68 labeled peptides target somatostatin receptors present on the surface of neuroendocrine tumor cells.
- **Applications**:
  - **Tumor Detection**: Especially for neuroendocrine tumors of the pancreas, gut, and lungs.
  - **Follow-up**: Monitors disease progression or response to therapy.

**C. Prostate-Specific Membrane Antigen (PSMA) PET/CT ğŸ“¸**

- **What is it?** PSMA is a cell surface protein overexpressed in prostate cancer cells. Radiolabeled molecules targeting PSMA provide a means to image prostate cancer.
- **Applications**:
  - **Recurrence Detection**: Particularly in patients with rising PSA levels post-treatment.
  - **Staging**: Identifying lymph node metastases or distant spread.

### **2ï¸âƒ£ Therapeutic Monitoring and Follow-up**

**A. Therapy Response Assessment ğŸ”„**
- **Metabolic Response Criteria**: Using FDG-PET, therapy response can be gauged by the reduction in FDG uptake in tumors post-therapy.
- **Morphological Response**: Combined with CT or MRI, reduction in tumor size or changes in tumor characteristics can be analyzed.


### **What is Theranostics?**

Theranostics is a term that combines "therapy" and "diagnostics." It pertains to agents or procedures that combine both diagnostic imaging and therapeutic intervention, offering a two-in-one approach to patient management. By utilizing the same molecule or a similar molecular pathway for both diagnosis and treatment, personalized care becomes possible.

### **1ï¸âƒ£ Theranostic Pairings in Oncology**

**A. Prostate Cancer ğŸ§¬**
   
- **Diagnostic**: PSMA PET/CT for identifying prostate cancer lesions.
- **Therapeutic**: Lutetium-177 or Actinium-225 labeled PSMA ligands for radionuclide therapy. These agents emit radiation that can kill prostate cancer cells which express PSMA.

**B. Neuroendocrine Tumors ğŸ§¬**

- **Diagnostic**: Gallium-68 DOTA peptides (like DOTATATE) for imaging neuroendocrine tumors.
- **Therapeutic**: Lutetium-177 labeled DOTA peptides for peptide receptor radionuclide therapy (PRRT). The radiation emitted targets and destroys the tumor cells with somatostatin receptors.

### **2ï¸âƒ£ Advantages of Theranostics ğŸŒŸ**

- **Tailored Treatment**: Only patients with positive diagnostic scans are treated, ensuring that the therapy will target the disease effectively.
- **Monitoring**: Ability to image and assess the response to therapy using the same agent.
- **Fewer Side Effects**: As the therapy is targeted, there's potentially reduced harm to healthy tissues.

## ğŸŒ **Immuno-PET in Oncology**

### **What is Immuno-PET?**

Immuno-PET combines the specificity of antibodies with the sensitivity of PET imaging. It employs radiolabeled antibodies or fragments of antibodies to target and visualize immune processes in real-time.

### **1ï¸âƒ£ Applications**

**A. Tumor Microenvironment Imaging ğŸ–¼ï¸**

- **Purpose**: Visualizing tumor-infiltrating lymphocytes, macrophages, and other immune cells.
- **Relevance**: Provides insights into how 'hot' or 'cold' a tumor is, aiding in the decision for immunotherapy.

**B. Assessing Immunotherapy Responses ğŸ”„**

- **Purpose**: To determine if a patient is responding to immunotherapy.
- **Relevance**: Early response detection can guide whether to continue or switch treatment strategies.

**C. Predicting Immunotherapy Success ğŸ“Š**

- **Purpose**: Predict which patients are likely to benefit from immunotherapy.
- **Relevance**: Can prevent unnecessary treatments and their associated side effects.

### **2ï¸âƒ£ Challenges and Advancements ğŸš§**

- **Size of Antibodies**: Traditional antibodies are large and might not penetrate tumors effectively. Smaller fragments or engineered versions are being developed to overcome this.
- **Radiolabeling**: Choosing the right radionuclide to label the antibody without affecting its specificity or causing rapid degradation.
- **Clearance**: Ensuring that non-bound antibodies are cleared swiftly from the bloodstream to improve imaging contrast.


  
- **Cardiology**: Blood flow and heart function.
- **Neurology**: Brain disorders like Alzheimer's, Parkinson's.
- **Endocrinology**: Thyroid and parathyroid glands.
- **Orthopedic**: Bone scans for fractures, infections, tumors.

[Back to top](#nuclear-medicine-cheatsheet)

## Therapeutic Applications
- **Radioiodine Therapy**: For overactive thyroid or thyroid cancer.
- **PRRT**: For neuroendocrine tumors.
- **Radionuclide Pain Palliation**: For bone metastases.

[Back to top](#nuclear-medicine-cheatsheet)

## Dosimetry & Safety
- **Dosimetry**: Measurement of radiation doses.
- **Radiation Protection**: Measures to minimize radiation exposure.
- **Radiation Biology**: Radiation's interactions with cells and effects.

[Back to top](#nuclear-medicine-cheatsheet)

## Instrumentation & Quality Control
- **Detectors**: Devices like Geiger-MÃ¼ller counters.
- **Quality Control**: Ensuring optimal operation of imaging systems.

[Back to top](#nuclear-medicine-cheatsheet)

## Recent Advances & Future Trends
- **Radiomics & AI**: Enhanced image analysis.
- **Immuno-PET**: Merging antibodies with PET imaging.
- **Theranostics**: Using identical molecules for diagnosis and treatment.

[Back to top](#nuclear-medicine-cheatsheet)

